HeartBeam Advances Commercial Launch, Reports Improved Q1 2026 Results
HeartBeam reported first-quarter 2026 results highlighting initial commercial partnerships in key U.S. markets and an $11.5 million public offering, as it advances its FDA-cleared 3D ECG platform for heart attack detection and ambulatory monitoring.
HeartBeam Inc. (NASDAQ: BEAT) announced first-quarter 2026 operational and financial results, underscoring progress in the commercial launch of its FDA-cleared cardiac monitoring platform. The company reported initial commercial partnerships in key U.S. markets, alongside advancements in its heart attack detection and ambulatory ECG patch initiatives.
Financially, HeartBeam posted a net loss of $4.7 million for the first quarter, an improvement from a $5.5 million loss in the prior-year period. Research and development expenses declined year over year as the company shifted focus toward commercialization. In April, the company completed a public offering that raised $11.5 million in gross proceeds, providing additional capital to support growth initiatives.
HeartBeam’s technology is designed to be the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. The platform received FDA clearance for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology.
The company’s 3D ECG technology aims to enable physicians to identify cardiac health trends and acute conditions outside of medical facilities, potentially redefining cardiac health management. For more details on the cleared indications for use, refer to HeartBeam’s indications page.
Investors can access the latest news and updates on HeartBeam at the company’s newsroom: https://ibn.fm/BEAT. The full press release is available at https://ibn.fm/guMCF.